The warning letter, stated plainly
Curex received warning letter number 716821, issued in September 2025 by the agency's drug centre, over the unlawful sale of unapproved and misbranded drugs. The letter names the company's own domain and quotes four marketing claims from it, including that the compounded products contained the same active ingredients as two named brand-name drugs and that the treatments were clinically proven.
A warning letter is a disclosure, not a finding of guilt, and this roster does not treat one as a reason to exclude a company or to score it down. Five of the sixty-five sellers here carry one. The letter number, the date and a link to the agency's own text sit on this row so a reader can weigh the agency's words rather than a summary of them.
The third fact is the one worth having, and it was measured rather than assumed: every phrase the letter quoted is gone from the live page. A census of the rendered priced page finds none of them. The nine remaining references to FDA approval on that page were each opened, and every one is a disclaimer saying compounded medications are not FDA-approved for safety or effectiveness, or that the company has no affiliation with either brand manufacturer.
What a reader should take from it is narrower than either extreme. Curex has been corrected once on how it describes its products, and it made the correction. That is a reason to read its marketing literally, and it is not a statement about what is in a vial.
One ongoing price for three products
Curex publishes three first-month prices, each attached to a specific product, and one ongoing price that covers all of them. There is no per-drug ongoing figure anywhere on the page.
This roster records that honestly rather than tidily: the price row carries the ongoing figure and says it is not scoped to a drug. Five of the sixty-five sellers here withhold the molecule behind a figure in some form, and this is the version where the molecules are named but the ongoing price is shared.
The practical consequence is simple and slightly uncomfortable. You can find out what your first month costs for the exact product you want, and you cannot find out from the page what month two costs for that product specifically. Ask.
The entry prices, and the timer next to them
Every product card advertises a first-month rate, and the lowest of the three is a fraction of the ongoing figure. Those are first-month prices and the cards say so, which is more disclosure than a lot of this field gives.
A countdown timer was running beside the lowest of them when this page was read, under a seasonal sale label. This site makes no claim that the timer resets or that the offer is not genuine. It is recorded because a reader who quotes that entry figure should know what it was attached to, and because a limited offer that is not in fact limited is a recognised advertising problem.
The entry rates are recorded on this row as introductory offers rather than as prices, which is the distinction that keeps a first month from being read as a year.
No membership, and a company that sells something else entirely
The GLP-1 page says there is no membership fee four separate times, including once in the words no membership fees, ever. Twenty-six of the sixty-five sellers here state something equivalent.
That statement has to be scoped, and on this company the scoping is not optional. Curex's main business is allergy immunotherapy, and its general pricing page is the allergy price page, carrying its own subscription fee and its own promotional figures. None of that belongs to the GLP-1 line, and a reader who lands on the wrong page will read a subscription charge as a GLP-1 charge.
The terms are dated to 2021, years before this company sold a GLP-1 at all. That is not an accusation; it is a document that has not been revisited since the product line it now governs came into existence.
A state footprint with a formulation-shaped hole in it
Curex publishes its footprint as all fifty states, and then names the one exception itself: in California, it says, state regulations limit prescriptions to oral tablet formulations only, and injectable medications are not available to California residents.
That is a fourth shape of state footprint, and a single list of states cannot express it. The array on this row says fifty states because that is the seller's published footprint; the exception lives in the price qualifiers and here, where it can be read as the condition it is.
For a California reader that is the whole review. The oral route is the route, and this is one of the few sellers in this comparison that has one to offer.
Curex's published pricing
| Medication | Price | Verified |
|---|---|---|
| Glp-1 (compounded) | $199/moThe ongoing rate, and Curex publishes one figure covering all three of its GLP-1 products rather than one per drug: "From $199/mo · No membership fee · Free shipping", with a stat block reading "$199 STARTING / MO". The lower card prices are first-month rates and are recorded separately. In California the seller states that "state regulations currently limit prescriptions to oral tablet formulations only — injectable medications are not available to California residents at this time". | September 2026source |
| Glp-1 (compounded-oral) | $199/moThe same ongoing rate the seller publishes for every GLP-1 plan — "From $199/mo · No membership fee · Free shipping" — applied to the oral dissolving tablet, which Curex sells for both compounds: "Curex offers oral dissolving tablets (ODT) for both semaglutide and tirzepatide." The card price of $149 is a first-month rate. This is the only formulation available to California residents, where the seller states regulations limit prescriptions to oral tablets. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 65 providers reviewed here are paid partners today; the other 61 are not. See how this works.
See Curex's current price →Good fit if
- Readers who want a compounded oral dissolving tablet rather than a weekly injection, which very few sellers here publish at all.
- Buyers in California, where this seller states the oral route is the only one available and prices it.
- People who want a written no-membership statement rather than an inference from silence.
- Readers who prefer a company with a documented regulatory correction they can read in full to one with no public record either way.
Look elsewhere if
- Anyone who needs to know what a specific drug costs after the first month. The ongoing figure covers all three products at once.
- Readers who will not buy from a company with an FDA enforcement history, which is a legitimate position and better taken with the letter in front of you.
- Buyers who need the compounding pharmacy or an individual prescribing clinician named. Neither appears.
- People who take a company's terms as current. This one is dated years before the product line it governs.
How this review was verified
- Read the GLP-1 landing page in a browser and audited every dollar element for computed opacity, visibility and a real laid-out rectangle before recording a figure.
- Recorded the ongoing figure with the compound left unscoped, because the seller publishes one ongoing price across three products and assigning it to a molecule would be this site inventing the scoping.
- Recorded the three first-month rates as an introductory offer with all three quoted in its qualifier, and logged the countdown timer that was running beside the lowest of them.
- Sourced the no-membership statement to the GLP-1 page rather than to the site's general pricing page, which belongs to a different product line and carries its own subscription fee.
- Read the warning letter in full from the agency's own record and recorded its number, its date, its issuing centre and the claims it quotes.
- Censused the live priced page for each of the four claims the letter quotes and found none of them. Opened every remaining reference to FDA approval on that page; each is a disclaimer. That measurement is reported as a fact, not as a verdict.
- Followed the terms link to its effective address rather than the one advertised, and read the date printed on the document itself.